News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,770 Results
Type
Article (14937)
Company Profile (299)
Press Release (266528)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79887)
Career Advice (211)
Deals (13339)
Drug Delivery (39)
Drug Development (50710)
Employer Resources (31)
FDA (5840)
Job Trends (5173)
News (145183)
Policy (10087)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (921)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21771)
ALS (124)
Alzheimer's disease (1030)
Antibody-drug conjugate (ADC) (241)
Approvals (6034)
Artificial intelligence (258)
Autoimmune disease (110)
Automation (9)
Bankruptcy (105)
Best Places to Work (4562)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (343)
Cancer (3127)
Cardiovascular disease (237)
Career advice (190)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (564)
Cervical cancer (14)
Clinical research (43672)
Collaboration (1148)
Company closure (2)
Compensation (591)
Complete response letters (39)
COVID-19 (1100)
CRISPR (86)
C-suite (551)
Cystic fibrosis (112)
Data (4316)
Denatured (15)
Depression (92)
Diabetes (254)
Diagnostics (1380)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (213)
Earnings (31663)
Editorial (25)
Employer branding (4)
Employer resources (30)
Events (51671)
Executive appointments (621)
FDA (7587)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (980)
Gene editing (182)
Generative AI (21)
Gene therapy (487)
GLP-1 (504)
Government (1151)
Grass and pollen (3)
Guidances (166)
Healthcare (6623)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1204)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (44)
IPO (7346)
IRA (12)
Job creations (871)
Job search strategy (154)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (10)
Legal (1402)
Liver cancer (41)
Longevity (11)
Lung cancer (419)
Lymphoma (248)
Machine learning (24)
Management (8)
Manufacturing (375)
MASH (130)
Medical device (2664)
Medtech (2673)
Mergers & acquisitions (6617)
Metabolic disorders (724)
Multiple sclerosis (102)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1949)
Neurotech (1)
NextGen: Class of 2026 (2039)
Non-profit (868)
Now hiring (30)
Obesity (329)
Opinion (126)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (327)
Peanut (43)
People (26666)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15475)
Phase 2 (20290)
Phase 3 (12824)
Pipeline (3240)
Policy (90)
Postmarket research (854)
Preclinical (6538)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (647)
Real estate (1449)
Recruiting (12)
Regulatory (9901)
Reports (19)
Research institute (973)
Resumes & cover letters (22)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (182)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2005)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (333)
Venture capital (70)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Last 7 days (344)
Last 30 days (1206)
Last 365 days (17803)
2026 (1652)
2025 (18104)
2024 (20557)
2023 (22420)
2022 (26826)
2021 (27817)
2020 (23375)
2019 (16243)
2018 (11754)
2017 (13757)
2016 (11844)
2015 (14360)
2014 (10396)
2013 (7495)
2012 (7542)
2011 (7632)
2010 (7444)
Location
Africa (165)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18265)
Australia (3122)
California (7074)
Canada (1836)
China (772)
Colorado (246)
Connecticut (252)
Delaware (235)
Europe (39230)
Florida (902)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (396)
India (35)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5578)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1645)
New Mexico (13)
New York (1765)
North Carolina (825)
North Dakota (6)
Northern California (3473)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1276)
Puerto Rico (9)
Rhode Island (25)
South America (226)
South Carolina (9)
Southern California (2806)
Tennessee (40)
Texas (904)
United States (23326)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
281,770 Results for "rapport therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Neuroscience
Rapport Jumps 180% on ‘Best Case’ Mid-Stage Data for Epilepsy Pill
Shares of Rapport Therapeutics popped Monday morning after Phase IIa data for RAP-219 exceeded analyst and Wall Street expectations, reducing seizures by almost 78% in patients with drug-resistant focal onset seizures.
September 8, 2025
·
2 min read
·
Heather McKenzie
Press Releases
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
·
1 min read
Press Releases
Rapport Therapeutics to Participate in Upcoming November 2025 Investor Conferences
November 5, 2025
·
1 min read
Press Releases
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
January 7, 2026
·
9 min read
Press Releases
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
November 6, 2025
·
12 min read
Press Releases
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
December 8, 2025
·
12 min read
Press Releases
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
November 26, 2025
·
7 min read
Press Releases
Rapport Therapeutics to Participate in TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
September 12, 2025
·
1 min read
Press Releases
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
August 7, 2025
·
13 min read
Press Releases
Rapport Announces Pricing of Public Offering of Common Stock
September 9, 2025
·
5 min read
1 of 28,177
Next
